- Higher Binding Affinity and In Vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab
-
Liddament , Husten J, Estephan T, Laine D, Mabon D, Pukac L, Lyons J, Clarke AW, Doyle A
- KMID: 2431860
- Allergy Asthma Immunol Res.
- 2019 Mar;11(2):291-298.
- doi: 10.4168/aair.2019.11.2.291
Reslizumab and mepolizumab are recently approved monoclonal antibodies for the treatment of severe (uncontrolled) eosinophilic asthma. Both are effective in neutralizing the function of interleukin-5 (IL-5). This study is the... -
- CITED
-
- Close
- SHARE
-
- Close
